Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy
Küçük Resim Yok
Tarih
2007
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
We prospectively investigated the effects of adding carvedilol to the standard treatment of ischemic and nonischemic dilated cardiomyopathy (DCM), by measuring the plasma levels of pro-inflammatory cytokines. Sixty patients with DCM (35 ischemic and 25 nonischemic) were divided into 2 subgroups: patients on standard therapy alone (digoxin, angiotensin-converting enzyme inhibitors, and diuretics) and patients on standard therapy plus carvedilol. Study participants' serum levels of tumor necrosis factor-? (TNF-?), interleukin-2 (IL-2), and interleukin-6 (IL-6) were measured at the beginning and again at the end of the study. Left ventricular ejection fraction and left ventricular diastolic function were evaluated by means of radionuclide ventriculography. In ischemic patients on carvedilol, levels of IL-6 and TNF-? dropped significantly (P=0.028 and P=0.034, respectively). In ischemic patients on standard treatment, plasma IL-2 levels were elevated after treatment (P=0.047). No significant differences occurred in IL-6 levels, while TNF-? levels were elevated (P=0.008). In nonischemic patients on carvedilol, IL-6 and TNF-? levels dropped significantly (P=0.018 and P=0.004, respectively). The left ventricular ejection fraction increased significantly (P=0.006). In nonischemic patients on standard treatment, no significant change occurred in any value. Carvedilol suppressed the plasma levels of TNF-? and IL-6 in both ischemic and nonischemic patients. The carvedilol effect was more pronounced in patients with nonischemic dilated cardiomyopathy than in those with ischemic disease. © 2007 by the Texas Heart® Institute.
Açıklama
Anahtar Kelimeler
Biological Markers/Blood; Carbazoles/Therapeutic Use; Cardiomyopathy, Dilated; Carvedilol; Cytokines/Blood; Heart Failure, Congestive; Interleukin-2; Interleukin-6; Tumor Necrosis Factor-Alpha; Ventricular Function, Left/Drug Effects, Carvedilol; Cytokine; Digoxin; Dipeptidyl Carboxypeptidase Inhibitor; Diuretic Agent; Interleukin 6; Tumor Necrosis Factor Alpha; Article; Blood Level; Congestive Cardiomyopathy; Controlled Study; Drug Effect; Drug Mechanism; Heart Left Ventricle Ejection Fraction; Heart Left Ventricle Enddiastolic Pressure; Human; Major Clinical Study; Protein Blood Level; Radioisotope Ventriculography; Adrenergic Alpha-Antagonists; Adrenergic Beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Cardiomyopathy, Dilated; Cytokines; Female; Heart Rate; Humans; Inflammation Mediators; Interleukin-2; Interleukin-6; Male; Middle Aged; Myocardial Ischemia; Propanolamines; Prospective Studies; Radionuclide Ventriculography; Stroke Volume; Treatment Outcome; Tumor Necrosis Factor-Alpha; Turkey; Vasodilator Agents; Ventricular Function, Left
Kaynak
Texas Heart Institute Journal
WoS Q Değeri
Scopus Q Değeri
Q3
Cilt
34
Sayı
1
